Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 8931-230
Fax: +49 (0)711 - 8931-323
send an Email


Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2011: 105/6 (June) pp. 933–1123
Pages: 1010-1023

Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions

P. Kirchhof (1), M. Nabauer (2), A. Gerth (2), T. Limbourg (3), T. Lewalter (4), A. Goette (5), K. Wegscheider (6), A. Treszl (6), T. Meinertz (7), M. Oeff (8), U. Ravens (9), G. Breithardt (1), G. Steinbeck (2), on behalf of the AFNET registry investigators

(1) Department of Cardiology and Angiology, University Hospital Münster, Münster, Germany; (2) Medizinische Klinik und Poliklinik I, Campus Grosshadern, Ludwig-Maximilians-University, Munich, Germany; (3) Institute for Research in Myocardial Infarction Ludwigshafen of the University of Heidelberg, Heidelberg, Germany; (4) University of Bonn, Bonn, Germany; (5) St Vincenz-Hospital Hospital Paderborn, Germany and Department of Clinical Pharmacology, University of Magdeburg Hospital, Magdeburg, Germany; (6) Department of Medical Biometry and Epidemiology, University Hospital, Hamburg-Eppendorf, Germany; (7) Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany; (8) Department of Medicine I, Brandenburg Municipal Hospital, Brandenburg, Germany; (9) Department of Pharmacology and Toxicology, Medical Faculty, Dresden University of Technology, Dresden, Germany


Atrial fibrillation, antithrombotic therapy, registry, access to health care, rhythm control therapy, level of care


Atrial fibrillation (AF) patients may receive treatment from specialists or from general medicine physicians representing different levels of care within a structured health care system. This “choice” is influenced by patient flow within a health care system, patient preference, and individual access to health care resources. We analysed how the postgraduate training and work environment of treating physicians affects management decisions in AF patients. Patient characteristics and treatment decisions were analysed at the time of enrolment into the registry of the German Atrial Fibrillation NETwork (AFNET). A total of 9,577 patients were enrolled from 2004 to 2006 in 191 German centres that belonged to the following four levels of care: 13 tertiary care centres (TCC) enrolled 3,795 patients (39.6%), 58 district hospitals (DH) enrolled 2,339 patients (24.4%), 62 office-based cardiologists (OC) enrolled 2,640 patients (27.6%), and 58 general practitioners or internists (GP) enrolled 803 patients (8.4%). Patients with new-onset AF were often treated in DH. TCC treated younger patients who more often presented with paroxysmal AF. Older patients and patients in permanent AF more often received outpatient care. Consistent with recommendations, younger patients and patients with non-permanent AF received rhythm control therapy more often. In addition, the type of centre affected the decision for rhythm control. Stroke risk was similar between centre types (mean CHADS2 scores 1.6 –1.9). TCC (68.8%) and OC (73.6%) administered adequate antithrombotic therapy more often than DH (55.1%) or GP (52.0%, p<0.001 between groups). Upon multivariate analysis, enrolment by TCC or OC was associated with a 1.60 (1.20–2.12, p=0.001) fold chance for adequate antithrombotic treatment. This difference between centre types was consistent irrespective of the type of stroke risk estimation (ESC 2001 guidelines, CHADS2 score), and also consistent when the recently suggested CHA2DS2-VASc score was used to estimate stroke risk. In conclusion, management decisions in AF are influenced by the education and clinical background of treating physicians in Germany. Inpatients receive more rhythm control therapy. Adequate antithrombotic therapy is more often administered in specialist (cardiologist) centres.

You may also be interested in...


N. Doll, M. Czesla, M. Borger, D. Merk, F. W. Mohr

Die Medizinische Welt 2007 58 4: 145-148

Neue Wirkstoffe

S. Zellerhoff (1), T. Lewalter (2, 3), L. Eckardt (1), A. Treszl (3, 4), K. Wegscheider (3, 4), G. Breithardt (1, 3)

Die Medizinische Welt 2013 64 6: 357-365

Neue Wirkstoffe

S. Zellerhoff (1), T. Lewalter (2, 3), L. Eckardt (1), A. Treszl (4, 3), K. Wegscheider (4, 3), G. Breithardt (1, 3)

Nervenheilkunde 2012 31 11: 813-820